Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma.

Detalhes bibliográficos
Autor(a) principal: Oliveira-Silva, Renato J.
Data de Publicação: 2016
Outros Autores: Carvalho, Ana-Carolina de, Viana, Luciano de Souza, Reis, R. M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/1822/46231
Resumo: Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that activates downstream signaling pathways, including the Ras-MEK-Erk and PI3K-AKT pathways, leading to cell proliferation, resistance to apoptosis, angiogenesis and the ability to metastasize. EGFR overexpression is a significant finding in cancer, particularly in head and neck cancer, where it is also associated with a poor prognosis. In recent years, several molecules have been designed to inhibit EGFR activation. Among the many available anti-EGFR drugs, only cetuximab was approved for the treatment of head and neck cancers. However, no predictive biomarkers of cetuximab response are currently known. In the present review, we provide an updated assessment of EGFR biology and its clinical impact in head and neck cancers. A special emphasis is placed on novel patents of EGFR-inhibitors that are anticipated to diversify the anti-EGFR therapies available to treat head and neck cancers. In particular, we outline a new class of irreversible multi-target inhibitors (e.g. afatinib, icotinib, CUDC-101), which may significantly contribute to new head and neck cancer therapies.
id RCAP_d495bab9b976b1b01ecf1467127bde84
oai_identifier_str oai:repositorium.sdum.uminho.pt:1822/46231
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma.Anti-EGFR patentsEGFREGFR overexpressionHead and neck squamous cell carcinomaTyrosine kinase inhibtorTargeted therapiestyrosine kinase inhibtorsScience & TechnologyEpidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that activates downstream signaling pathways, including the Ras-MEK-Erk and PI3K-AKT pathways, leading to cell proliferation, resistance to apoptosis, angiogenesis and the ability to metastasize. EGFR overexpression is a significant finding in cancer, particularly in head and neck cancer, where it is also associated with a poor prognosis. In recent years, several molecules have been designed to inhibit EGFR activation. Among the many available anti-EGFR drugs, only cetuximab was approved for the treatment of head and neck cancers. However, no predictive biomarkers of cetuximab response are currently known. In the present review, we provide an updated assessment of EGFR biology and its clinical impact in head and neck cancers. A special emphasis is placed on novel patents of EGFR-inhibitors that are anticipated to diversify the anti-EGFR therapies available to treat head and neck cancers. In particular, we outline a new class of irreversible multi-target inhibitors (e.g. afatinib, icotinib, CUDC-101), which may significantly contribute to new head and neck cancer therapies.The authors would like to acknowledge Dr. Laura Mussel white for critical revision of the manuscript. André L. Carvalho and Rui M. Reis have a National Counsel of Technological and Scientific Development (CNPq) scholarship. A.C.C, has a FAPESP (2013/13834-7) scholarship.info:eu-repo/semantics/publishedVersionBentham Science PublishersUniversidade do MinhoOliveira-Silva, Renato J.Carvalho, Ana-Carolina deViana, Luciano de SouzaReis, R. M.20162016-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/46231eng1574-892810.2174/157489281166616030912123826955963http://www.eurekaselect.com/140320/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:22:49Zoai:repositorium.sdum.uminho.pt:1822/46231Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:16:22.650422Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma.
title Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma.
spellingShingle Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma.
Oliveira-Silva, Renato J.
Anti-EGFR patents
EGFR
EGFR overexpression
Head and neck squamous cell carcinoma
Tyrosine kinase inhibtor
Targeted therapies
tyrosine kinase inhibtors
Science & Technology
title_short Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma.
title_full Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma.
title_fullStr Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma.
title_full_unstemmed Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma.
title_sort Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma.
author Oliveira-Silva, Renato J.
author_facet Oliveira-Silva, Renato J.
Carvalho, Ana-Carolina de
Viana, Luciano de Souza
Reis, R. M.
author_role author
author2 Carvalho, Ana-Carolina de
Viana, Luciano de Souza
Reis, R. M.
author2_role author
author
author
dc.contributor.none.fl_str_mv Universidade do Minho
dc.contributor.author.fl_str_mv Oliveira-Silva, Renato J.
Carvalho, Ana-Carolina de
Viana, Luciano de Souza
Reis, R. M.
dc.subject.por.fl_str_mv Anti-EGFR patents
EGFR
EGFR overexpression
Head and neck squamous cell carcinoma
Tyrosine kinase inhibtor
Targeted therapies
tyrosine kinase inhibtors
Science & Technology
topic Anti-EGFR patents
EGFR
EGFR overexpression
Head and neck squamous cell carcinoma
Tyrosine kinase inhibtor
Targeted therapies
tyrosine kinase inhibtors
Science & Technology
description Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that activates downstream signaling pathways, including the Ras-MEK-Erk and PI3K-AKT pathways, leading to cell proliferation, resistance to apoptosis, angiogenesis and the ability to metastasize. EGFR overexpression is a significant finding in cancer, particularly in head and neck cancer, where it is also associated with a poor prognosis. In recent years, several molecules have been designed to inhibit EGFR activation. Among the many available anti-EGFR drugs, only cetuximab was approved for the treatment of head and neck cancers. However, no predictive biomarkers of cetuximab response are currently known. In the present review, we provide an updated assessment of EGFR biology and its clinical impact in head and neck cancers. A special emphasis is placed on novel patents of EGFR-inhibitors that are anticipated to diversify the anti-EGFR therapies available to treat head and neck cancers. In particular, we outline a new class of irreversible multi-target inhibitors (e.g. afatinib, icotinib, CUDC-101), which may significantly contribute to new head and neck cancer therapies.
publishDate 2016
dc.date.none.fl_str_mv 2016
2016-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/1822/46231
url http://hdl.handle.net/1822/46231
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1574-8928
10.2174/1574892811666160309121238
26955963
http://www.eurekaselect.com/140320/article
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Bentham Science Publishers
publisher.none.fl_str_mv Bentham Science Publishers
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799132612207312896